| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.08 | 0.008 |
| mRNA | CHIR-99021 | GDSC1000 | pan-cancer | AAC | -0.08 | 0.01 |
| mRNA | PIK-93 | CTRPv2 | pan-cancer | AAC | 0.086 | 0.01 |
| mRNA | TG-101348 | CTRPv2 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.081 | 0.01 |
| mRNA | VX-11e | GDSC1000 | pan-cancer | AAC | -0.082 | 0.01 |
| mRNA | bid1870 | gCSI | pan-cancer | AAC | -0.13 | 0.02 |
| mRNA | TW 37 | GDSC1000 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | SKI-II | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.077 | 0.02 |